ASCVD Clinical Trial
Official title:
The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)
cvMOBIUS is a North American registry of patients with ASCVD aimed at understanding patterns of care in ASCVD while evaluating the real world effectiveness of PCSK9 inhibitors.
The purpose of this registry is to evaluate the effectiveness of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (PCSK9i) to reduce cardiovascular events among subjects presenting with a recent atherosclerotic cardiovascular disease (ASCVD) event in real-world practice. A total of 8500 patients with a recent cardiovascular event who are likely to be eligible for non-statin lipid lowering therapy will be enrolled and followed prospectively for five years. In addition, the study will assess longitudinal patterns of lipid control, clinical outcomes, and LLT including statins, ezetimibe, and PCSK9 inhibitors in adults with an ASCVD event and/or revascularization. This study will also compare the clinical characteristics and outcomes of subjects enrolled in both arms of the registry to understand the strengths and limitations of data harvested directly from electronic health record (EHR) systems as compared with prospectively collected information. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05390892 -
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
|
Phase 4 | |
| Active, not recruiting |
NCT05088759 -
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management
|
N/A | |
| Not yet recruiting |
NCT04093440 -
Cardiometabolic Syndrome Response to Therapeutic Lifestyle Changes
|
N/A | |
| Recruiting |
NCT05611307 -
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
|
||
| Completed |
NCT03400800 -
Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
|
Phase 3 | |
| Recruiting |
NCT03606824 -
Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study)
|
N/A | |
| Completed |
NCT03494270 -
High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients
|
Phase 4 | |
| Recruiting |
NCT05579626 -
Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)
|
N/A | |
| Recruiting |
NCT06005597 -
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
|
Phase 3 | |
| Active, not recruiting |
NCT06295861 -
Prospective Cohort Study of Panvascular Disease
|
||
| Completed |
NCT03399370 -
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
|
Phase 3 | |
| Not yet recruiting |
NCT05976893 -
Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
|
Phase 4 | |
| Completed |
NCT03474562 -
High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension
|
Phase 4 | |
| Completed |
NCT03814187 -
Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
|
Phase 3 | |
| Not yet recruiting |
NCT05858879 -
Notification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NOTIFY-ASCVD)
|
N/A |